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WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT
• Lamivudine is widely used in human immunodeficiency virus-infected children.
• Small populations or populations with narrow age ranges have been used before to investigate the pharmacokinetics of lamivudine.
• Dosing in children should be guided on the basis of understanding the developmental changes in pharmacokinetics of drugs.
WHAT THIS STUDY ADDS
• Bodyweight best explained age-related pharmacokinetic variability.
• In 94.5% and 35.8% of the children weighing > and <14 kg adult target steady state AUC 0-24h of 8.9 mg·h l -1 was reached.
• This study indicates that daily dose should be increased to 10 mg kg -1 for children weighing <14 kg to reach the target area under the daily plasma concentration-time curve.
Introduction
Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI) that is widely used as part of the treatment of human immunodeficiency virus (HIV)-infected children. It is currently recommended as part of first-line NRTI backbone together with either a protease inhibitor or non-nucleoside reverse transcriptase inhibitor [2] . Lamivudine is available in solid and liquid dosage forms, as well as in single entity and fixed dose combination products. Currently, a daily dose of 8 mg/kg is recommended for children, independent of their age and bodyweight [2, 3] . Several issues have been raised concerning the treatment with lamivudine, such as bioavailability issues [3] [4] [5] [6] [7] and possible underdosing in the youngest age group [8] [9] [10] .
There have been several studies on the pharmacokinetics of lamivudine in children. Most studies applied noncompartmental analysis [5, 6, [9] [10] [11] [12] [13] [14] [15] [16] and some developed a population pharmacokinetic model [8, [17] [18] [19] [20] [21] . Most of these studies were based on a small number of children, narrow age ranges or the relationship between parameters and covariate was fixed a priori. None of the models has been validated externally, in other words the models have not been evaluated in how well they generalize to new data that have not been included in the model-building dataset.
As highlighted before, dosing in children should be based on the understanding of the developmental changes in the pharmacokinetic and/or pharmacodynamic relation of drugs instead of applying the adult mg/kg dose to children [22] [23] [24] . For lamivudine, the area under the daily plasma concentration-time curve (AUC 0-24h ) is mainly used as a surrogate for the intracellular exposure to lamivudine triphosphate. In adults, an average steady state AUC 0-24h of 8.9 mg·h l -1 is reached after administration of a daily dose of 300 mg which is the licensed dose with proven efficacy [3] . Also, in children, this value is used as a target for lamivudine exposure [8, 16, 17, 25] .
The objectives of this study were to characterize agerelated changes in lamivudine pharmacokinetics in infants, children and adolescents, and to test how well this model can be generalized to new patients not included in the model-building dataset. Based on the developed population pharmacokinetic model, lamivudine exposure upon currently used dosing recommendations was evaluated and, when necessary, a new dose will be calculated for subgroups in which target AUC 0-24h was not reached.
Methods

Patients and treatment
Model building was based on data from two datasets of in total 85 children using lamivudine twice daily [26] . These datasets were chosen for model-building, because almost the entire paediatric age range was represented and body weight of all of the children was known. The first dataset consisted of 64 children, aged 0.5-14.9 years, who participated in the CHAPAS1 trial [26] . CHAPAS1 was an open, randomized controlled phase I/II trial designed to assess the appropriate dosing of and adherence to Triomune. Lamivudine was administered in a fixed-dose combination tablet of lamivudine, nevirapine and stavudine. Daily dosing was based on acquiring an appropriate nevirapine dose. Daily lamivudine dose varied between 60 and 240 mg (6.3-17.6 mg kg -1 ). In the second dataset, 21 children, aged 1.7-18.0 years, were included in whom therapeutic drug monitoring on lopinavir was performed as part of routine clinical care. In the available samples, lamivudine concentrations were also determined. Lamivudine was dosed orally according to the PENTA guideline valid at that time [27] . Daily lamivudine dose varied between 80 and 300 mg (5.1-10.5 mg kg -1 ) for the children included in this cohort.
An overview of the patient characteristics is given in Table 1 .
External evaluation of the model was performed with two external datasets [9, 15, 16, 28] . The first external dataset consisted of 24 children, aged 1.6-17.3 years, in whom therapeutic drug monitoring on lopinavir was performed. Lamivudine concentrations were determined on samples from different occasions (range: 1-10 occasions). Sixteen of these 24 children participated in the RONDO trial [28] . Lamivudine was dosed both once and twice daily according to the PENTA guideline valid at that time and daily dose varied between 90 and 300 mg (3.9-10.2 mg kg -1 ) [27] .
The second external dataset consisted of 77 children, aged 0.4-12.8 years, who were included in three studies: PENTA13 [9] , PENTA15 [16] and ARROW [15] . All three studies were cross-over studies to compare the pharmacokinetics of once daily lamivudine dosing vs. twice daily dosing [9, 15, 16] . Daily dose varied between 60 and 300 mg (4.9-15.0 mg kg -1 ). An overview of the patient characteristics is given in Table 1 . Data on different dosing occasions of six children were included in both the modelbuilding dataset as well as in the dataset for external validation.
The study protocols of the included studies were approved by medical ethical committees and regulatory bodies in each participating country and clinical site. All studies were performed in full conformance with the principles of the Declaration of Helsinki. All the patients were only included if written informed consent was given by the parents.
Blood sampling and assay
For all children included in the model-building datasets and the second external dataset, at least one complete concentration-time profile after dosing was available (≥6 samples). This also applied for 15 children (63%) included in the first external dataset. Sampling was performed until the end of the dosing interval.
For the data from the CHAPAS1 trial, PENTA trials and therapeutic drug monitoring study, lamivudine concentrations were measured using a high-performance liquid chromatography assay with ultraviolet detection [29] . The lower limit of quantification was 0.05 mg l -1 . As only one value from the model-building datasets and 12 values from external validation datasets were below the limit of quantification, these values were excluded from the analysis (M1 method [30] ). For the data from the ARROW trial, lamivudine was measured using a high-performance liquid chromatography assay with tandem mass spectrometry detection. The lower limit of quantification was 0.0025 mg l -1 .
Pharmacokinetic analysis and model evaluation
Model building was performed in four different steps: 1) testing of both a one-and two-compartment model and different absorption models in order to select a structural model; 2) selection of a statistical model; 3) covariate analysis; and 4) model evaluation. For oral absorption, both a zero order and first order model, a lag time model [31] , transit compartment model [31] and combined absorption models were evaluated. Discrimination between structural models was achieved by comparison of the objective function value (OFV) and 
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64 (1) 21 (1) 85 (1) 88 ( Pharmacokinetic analysis of lamivudine in children for dose evaluation the degrees of freedom. A decrease in the OFV of more than 3.8 points was considered statistically significant for the structural model (P < 0.05 based on χ 2 distribution). The goodness-of-fit plots (observed vs. both individual-and population-predicted concentrations and conditional weighted residuals vs. both time and population predictions) were evaluated. Improvement of individual plots, confidence intervals of the parameter estimates and the correlation matrix were also assessed.
Covariate analysis
Covariates were plotted against individual posthoc parameter estimates and the weighted residuals to visualize potential relationships. The covariates bodyweight, age, height and formulation were evaluated. Potential covariates were separately implemented in the model, using a linear or power equation (1) .
where P i represents the individual parameter estimate of the i th subject, P p is the population parameter estimate, cov is the covariate and k is the exponent. K was fixed at 1 for a linear function or estimated for a power function. The framework proposed by Krekels et al. [32] to systematically evaluate the descriptive and predictive performance of a paediatric model was used as a guide to discriminate between different covariate models. A decrease in OFV of at least 7.8 points was applied to evaluate covariates in forward inclusion. In backward deletion, a more stringent P-value of <0.001 was used (a decrease in OFV of at least 10.83 points). When two or more covariates were found to significantly improve the model, the covariate causing the largest decrease in OFV was kept in the model. In order to be retained in the model, additional covariates had to reduce this OFV further. The clinical relevance of a covariate relationship was also considered [32] . In order to confirm the final covariate model, individual and population parameter estimates were plotted against the most predictive covariate to evaluate whether the individual predicted parameters were equally distributed around the population predicted parameters.
Internal evaluation procedure
The final model was evaluated using three methods [32] : the bootstrap method for model stability and precision [33] , and both the normalized prediction distribution error (NPDE) method [34, 35] of the model parameter estimates and a visual predictive check [36] for model accuracy. The model-building dataset was resampled to produce 2000 new datasets of the same size, containing a different combination of individuals. The final model was sequentially fitted to all of these newly generated datasets. The parameter estimates were summarized in terms of median values and 95% parametric confidence intervals, and were compared with the estimates obtained from the model-building datasets.
External evaluation procedure
External evaluation of the model was performed with two external datasets [9, 15, 16, 28] , as described above. These datasets were not included when the model was fitted to the data. The final pharmacokinetic model was used to simulate concentrations for each data point in the two external datasets. Both interindividual and residual variability were included in the simulations. Additionally, the final pharmacokinetic model was used to compute the NPDE [34, 35] for each of the external datasets. Finally, the parameters of the final model were re-estimated on the basis of the two model-building datasets combined with both external datasets.
Evaluation of currently used dosing guidelines
Intracellular triphosphate levels of lamivudine have been found to be predictive to anti-HIV response with the intracellular triphosphate levels being directly related to the lamivudine plasma concentration [37] . Target AUC 0-24h was 8.9 mg·h l -1 , which is the AUC 0-24h obtained in adults after once daily administration of 300 mg being the licensed dose for which efficacy has been shown [3] . For the first available dosing occasion per individual, AUC 0-24h was noncompartmentally derived from the estimated individual parameter estimates. Based on the results, a dose adaptation was proposed for subgroups of children not reaching the target AUC 0-24h .
Software
The pharmacokinetic analysis and evaluation procedures were performed using the nonlinear mixed-effects modelling software NONMEM version 7. 
Results
Population pharmacokinetic model-building
Model building was based on 638 observations from 85 children while external evaluation was based on 1423 observations from 101 children ( Table 1) . A two-compartment model with sequential zero order and first order absorption best described the data. A two-compartment model was preferred over a one-compartment model, since the modelbuilding data, and especially the highest concentrations, were more accurately described with a two-compartment model (dOFV: 140.701 points). The final model was parameterized in terms of a zero-order absorption phase (D1), which was followed by a first order absorption process (K a ) (i.e. sequential zero order and first order absorption model), apparent clearance (Cl/F), intercompartmental clearance (Q/F), and apparent volumes of distribution of the central compartment (V 2 /F) and peripheral compartment (V 3 /F). Because there were difficulties estimating reliable values for V 3 /F, the model was simplified by equalising V 3 /F to V 2 /F. The residual variability was best described using a combined additive and proportional error model.
Systematic covariate analysis
The covariate analysis identified bodyweight as the most important covariate for both Cl/F and V 2 /F. After implementation of this covariate, OFV decreased with 47.573 points. The exponent for the effect of bodyweight on Cl/F was 0.506 (20.2%) and for the effect on V 2 /F 0.489 (32.3%). The parameter estimates for the simple and final model are shown in Table 2 . In Figure 1 , the individual estimates of variability of Cl/F and V 2 /F are plotted against bodyweight for the simple and final models. A significant part of the interindividual variability is explained after inclusion of bodyweight as a covariate, with a decrease of 8.9% in the interindividual variability of Cl/F and 9.5% in the interindividual variability of V 2 /F ( Internal evaluation of the final pharmacokinetic model Table 2 gives an overview of the parameter estimates of the simple and final model, together with the values obtained from the bootstrap analysis. The median estimated values based on the bootstrap were within 10% of the values obtained in the final model. In Figure 2A ,B,C,D, the goodness-of-fit plots, observed vs. individual-and population predicted concentrations and conditional weighted residuals vs. population predicted concentrations and time, are given for the final model, while in Figure 2E a histogram of the NPDE is shown. No trend was seen in the NPDE vs. time or vs. predicted concentrations (results not shown). A visual predictive check shows the adequacy of the model (Figure 3 ). Figure S1 shows that the data in different weight groups are well described.
External evaluation of the final pharmacokinetic model
The predictive performance of the final model was evaluated using two external datasets [9, 15, 16, 28] (Table 1) . In Figure 2 , observed vs. individual predicted concentrations ( Figure 2F,I ) and observed vs. population-predicted concentrations ( Figure 2G ,J) are given for both external datasets. Additionally, the histograms of the NPDE are shown in Figure 2H ,K. While the final model is able to predict the data in external dataset 2 without bias, a slight bias is seen for external dataset 1, in which the sampling was more sparse, compared to the model-building datasets. This bias is observed in Figure 2G , which shows observed vs. population predicted concentrations, as well as in Figure 2H . When the parameters of the final model were re-estimated on the basis of the model-building datasets and external datasets, fairly similar parameter values were obtained ( Table 2 ). The concentrations in all four datasets could be well described by this model without bias and with adequate precision ( Figure S2 ).
Evaluation of currently used dosing guidelines
Of the children with a bodyweight >14 kg, 94.5% reached the adult target AUC 0-24h of 8.9 mg·h l -1 with the currently administered daily dose. However, this did not hold for all children with a bodyweight <14 kg (Figure 4) . If the daily dosage for these children is increased to at least 10 mg kg
it is expected that most children will have adequate exposure to lamivudine (64.2% before dose adaptation, 92.5% thereafter; Figure 5 ).
Discussion
A model-based approach has been applied in order to describe the pharmacokinetics of lamivudine in children. The model was based on a large and relatively rich dataset, since for most of the children at least six samples within one dosing interval were available. Also, the full paediatric age range is covered, with a large proportion of children below the age of 3 years [n = 16 (18.8%) in the dataset used for model-building; n = 41 (22.8%) in total]. The two-compartment model used to describe the data is in agreement with previously developed models [8, 17, 21, 39] . In order to obtain reliable estimates of the peripheral volume, the model had to be simplified by stating that the central and peripheral volume of distribution were equal to each other (Table 2) ; however, this did not lead to reduced descriptive or predictive values (Figures 2 and S1 ). Bodyweight best predicted the developmental changes in both apparent lamivudine clearance and apparent central volume of distribution. This is consistent with previous studies [8, [17] [18] [19] [20] [21] . Although the typical parameter estimates for an individual of 16.6 kg are comparable, the estimations of both scaling exponents were lower in our analysis [8, [17] [18] [19] [20] [21] . Remarkable is the difference in the relationship between apparent volume of distribution and bodyweight. The majority of the performed studies fixed this relationship a priori to 1 [8, 17, [19] [20] [21] . Piana et al. found an exponent of 0.635 [18] , which seems very close to the exponent of 0.489 we identified (Table 2) . In this respect, we emphasize that the exponent we identified is the exponent for Cl/F or for V 2 /F and since no data after intravenous administration of lamivudine were available, we cannot distinguish between the influence of bodyweight on bioavailability, clearance and/or volume of distribution.
The stability of the final model was indicated by the NPDE and the bootstrap as well as the ability to predict external dataset 2 accurately. For external dataset 1, the predictive performance was somewhat biased. This may be explained by the (sparse) nature of the data available in that dataset. The data were derived from routine clinical care, where data collection is probably less accurate. When the data from all datasets were combined and analysed together, the data in external dataset 1 were described without any bias ( Figure S2) .
The target AUC 0-24h of 8.9 mg·h l -1 that has been identified in adults was reached in 85.6% of the children. However, 35.8% of the children with a bodyweight below 14 kg did not Pharmacokinetic analysis of lamivudine in children for dose evaluation reach this target. It was shown previously that lamivudine exposure was lower in the youngest group of children compared to older and heavier children [8] [9] [10] 40] . For children older than 5 months and with a bodyweight below 14 kg we calculated that the target AUC 0-24h can be reached with a dose of at least 10 mg kg -1 day -1
, based on the expected apparent clearance. The same dose was also proposed by Bouazza et al. for children with a body weight <17 kg [8] . We chose our cutoff body weight in line with the approved dosing regimens of the antiretroviral drugs frequently used in children [2, 41] and with the data found in our model. The relativeness of this cut-off point and potential considerations for paediatric fixed dose combinations has already been described before [42] . In the model, the absorption phase was relatively difficult to describe, which can partly be explained by the limited data available for that part of the concentration-time profile. In most paediatric population pharmacokinetic models for lamivudine, a first-order absorption model is used [8, 17, 19, 20, 39] . However, also a delay in absorption with either a lag-time [18] or transit compartments [21] has been described. During model-building, all these absorption models, as well as a zero-order absorption, were tested. A sequential zero-and first-order absorption model was finally found to best describe the data ( Table 2) .
A limitation of the current study is that we could not fully study the influence of the formulation on the pharmacokinetics. As shown before, the type of drug formulation can affect the lamivudine exposure significantly in children [5, 6, 20, 25] . However, similar to previous population pharmacokinetic studies [17, 18, 43] , the formulation used by the children could not be identified as a possible covariate in our study as information on the formulation used was not complete for all of the children ( Table 1) . Next to this, we could not study the influence of renal function in this analysis. Lamivudine is a renally excreted drug [3, 4] and it has been shown in adults that renal function can affect the pharmacokinetics of lamivudine [4, [44] [45] [46] . Even though in several paediatric studies, serum creatinine could not be identified as possible covariate for clearance [17, 19, 20] , we could not study this covariate as information on renal function was incomplete.
Figure 3
Visual predictive check of the final pharmacokinetic model. The dots represent observed concentrations, the solid line represents the median of the simulated profile and the dotted lines represent the 95% confidence interval. The grey shaded areas are the 95% confidence intervals for the same percentiles of the simulations Figure 4 Simulated area under the daily plasma concentration-time curve (AUC 0-24h ) vs. daily dose administered (mg) split by bodyweight: ≤14 kg, 14-21 kg, 21-30 kg and >30 kg. The dotted line indicates an AUC 0-24h of 8.9 mg·h l -1 (adult target for once daily dosing [3] ). Vertically occurring sequences of dots occur because of fixed dose tablets
In conclusion, lamivudine pharmacokinetics were best described by a two-compartment model with sequential zero-order and first-order absorption. Bodyweight was found as covariate on apparent clearance and apparent central volume of distribution, both in a power function (exponent of respectively 0.506 and 0.489). The model can be generalized to patients not included in the modelbuilding dataset. In order to identify whether these (nonlinear) changes result from changes in bioavailability, clearance and/or volume of distribution, future analysis, which includes intravenously administered lamivudine, is warranted. The results of this study suggest that the currently recommended dose for children aged 5 months to 18 years and with a body weight below 14 kg should be increased to at least 10 mg kg À1 day À1 in order to reach an AUC 0-24h of 8.9 mg·h l -1 .
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